Remix Therapeutics Enters Collaboration with Janssen to Advance Small Molecule Therapeutics Using REMaster Drug Discovery Platform to Modulate RNA Processing
- Thursday, February 17, 2022, 7:12
- Environment
- Add a comment
CAMBRIDGE, Mass., Feb. 17, 2022 /PRNewswire/ — Remix Therapeutics (Remix), a biotechnology company developing small molecule therapies designed to reprogram RNA processing and address the underlying drivers of disease, today announced a strategic collaboration with Janssen Pharmaceutica…
About the Author
adminasapcorp has written 41806 stories on this site.